Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2002 Oct-Dec;26(2-3):317-46.
doi: 10.1385/MN:26:2-3:317.

Acute neuronal injury, excitotoxicity, and the endocannabinoid system

Affiliations
Review

Acute neuronal injury, excitotoxicity, and the endocannabinoid system

Mario van der Stelt et al. Mol Neurobiol. 2002 Oct-Dec.

Abstract

The endocannabinoid system is a valuable target for drug discovery, because it is involved in the regulation of many cellular and physiological functions. The endocannabinoid system constitutes the endogenous lipids anandamide, 2-arachidonoylglycerol and noladin ether, and the cannabinoid CB1 and CB2 receptors as well as the proteins for their inactivation. It is thought that (endo)cannabinoid-based drugs may potentially be useful to reduce the effects of neurodegeneration. This paper reviews recent developments in the endocannabinoid system and its involvement in neuroprotection. Exogenous (endo)cannabinoids have been shown to exert neuroprotection in a variety of in vitro and in vivo models of neuronal injury via different mechanisms, such as prevention of excitotoxicity by CB1-mediated inhibition of glutamatergic transmission, reduction of calcium influx, and subsequent inhibition of deleterious cascades, TNF-alpha formation, and anti-oxidant activity. It has been suggested that the release of endogenous endocannabinoids during neuronal injury might be a protective response. However, several observations indicate that the role of the endocannabinoid system as a general endogenous protection system is questionable. The data are critically reviewed and possible explanations are given.

PubMed Disclaimer

References

    1. Ann Neurol. 2000 Aug;48(2):257-61 - PubMed
    1. Mol Pharmacol. 1995 Sep;48(3):443-50 - PubMed
    1. J Neurochem. 2001 Sep;78(6):1415-27 - PubMed
    1. Epilepsia. 2001 Mar;42(3):321-7 - PubMed
    1. J Neurochem. 1998 Feb;70(2):671-6 - PubMed

MeSH terms

LinkOut - more resources